Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions.
Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it can be delayed or prevented by effective disease-modifying therapies (DMTs). SPMS can be active or not active, and with progression or without progression, depending on the presence of relapses, new MRI activity, or increased disability.
SPMS is diagnosed by a neurologist based on the clinical history, neurological exam, and MRI scans. MRI scans can show the level of cell death and brain atrophy in MS. Treatment for SPMS may include DMTs to reduce the risk of relapses and slow down the progression of disability, as well as symptom management and rehabilitation strategies to improve quality of life.
The Secondary Progressive Multiple Sclerosis (SPMS) drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Secondary Progressive Multiple Sclerosis (SPMS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 42 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Secondary Progressive Multiple Sclerosis (SPMS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Secondary Progressive Multiple Sclerosis (SPMS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Secondary Progressive Multiple Sclerosis (SPMS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB Science SAAbata Therapeutics
AbbVie Inc
Apimeds Inc
Biogen Inc
BrainStorm Cell Therapeutics Inc
Chiome Bioscience Inc
Clene Inc
Denali Therapeutics Inc
EA Pharma Co Ltd
Ever Supreme Bio Technology Co Ltd
F. Hoffmann-La Roche Ltd
GeNeuro SA
Glialogix Inc
Guangzhou Lupeng Pharmaceutical Co Ltd
Immune Response BioPharma Inc
Immunic Inc
Imstem Biotechnology Inc
InnoBioscience LLC
MedDay SA
MediciNova Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mitochon Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
NeuroGenesis Ltd
Novartis AG
Oryzon Genomics SA
Ossianix Inc
Polpharma Biologics SA
Sana Biotechnology Inc
Sanofi
Statera Biopharma Inc
Stem Cell Medicine Ltd
Sungkyunkwan University
Tiziana Life Sciences Plc
UCB SA
Table of Contents
Table
Figures
Frequently asked questions